<PAGE>  1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 1997

Commission file number  0-28092

Medical Information Technology, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Massachusetts
(State or Other Jurisdiction of Incorporation or Organization)

04-2455639
(I.R.S. Employer Identification No.)

Meditech Circle, Westwood, MA
(Address of Principal Executive Offices)

02090
(Zip Code)

781-821-3000
(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.  Yes [X] No [ ]

The number of shares of Common Stock, $.25 par value, outstanding at December
31, 1997 was 16,087,212
<PAGE>  2
Index to Form 10-K

Part I

    Item 1 - Business                                                   Page 3

    Item 2 - Properties                                                 Page 5

    Item 3 - Legal Proceedings                                          Page 6

    Item 4 - Submission of Matters to a Vote of Security Holders        Page 6

Part II

    Item 5 - Market for Registrant's Common Equity and Related
             Stockholder Matters                                        Page 6

    Item 6 - Selected Financial Data                                    Page 6

    Item 7 - Management's Discussion and Analysis of Financial
             Condition and Results of Operations                        Page 7

    Item 8 - Financial Statements and Supplementary Data                Page 8

    Item 9 - Changes in and Disagreements with Accountants on
             Accounting and Financial Disclosure                        Page 8

Part III

    Item 10 - Directors and Executive Officers of the Registrant        Page 8

    Item 11 - Executive Compensation                                    Page 10

    Item 12 - Security Ownership of Certain Beneficial Owners
              and Management                                            Page 11

    Item 13 - Certain Relationships and Related Transactions            Page 11

Part IV

    Item 14 - Exhibits, Financial Statement Schedules, and Reports
              on Form 8-K                                               Page 12

    Signatures                                                          Page 12
<PAGE>  3
Part I

    Item 1 - Business

COMPANY OVERVIEW

Medical Information Technology, Inc. (MEDITECH or the Company) was founded
in 1969 to develop and market information system software for the hospital
industry.  1997 revenues reached $193.8 million and at year-end MEDITECH had a
product backlog of $130 million and more than 1,800 employees.

By the end of 1997 MEDITECH had over 1,050 active hospital customers throughout
the U.S., Canada and the U.K., as well as a backlog of almost 100 hospitals
waiting implementation.  The implementation process consists of teaching
hospital personnel about the operation of the software as well as training them
on how to use it in their daily activity.  Once the hospital goes live,
MEDITECH maintains and updates the software thereafter.

HOSPITAL SOFTWARE

Initially MEDITECH developed a software product to automate one of the main
hospital departments, the clinical laboratory that performs various diagnostic
tests on blood and urine specimens.  Within a few years, this product became
standardized, thereby requiring minimal adaptation to meet the individual needs
of a typical customer.  MEDITECH extended the concept and developed additional
software products for the rest of a hospital's clinical departments.
Eventually, it moved into the financial area by developing a hospital billing
and accounts receivable product as well as various general accounting products.

Although the individual products could be operated in a stand alone fashion,
a hospital achieved maximum effectiveness when they were used in an integrated
mode, sharing access to the common clinical and financial records of the
hospital.  This concept ultimately led to MEDITECH developing the so-called
hospital information system, a cohesive set of software products designed from
the onset to work in conjunction with the overall operation of the hospital and
to minimize the need for specialized interfaces.

COMPUTER HARDWARE

Software requires extensive computer and communication equipment to function.
In spite of this, MEDITECH continues to be a pure software company, limiting
itself to specifying the aggregate components needed as well as suggesting
typical configurations from certain hardware vendors.  The responsibility is
left to the hospital to purchase the requisite hardware and secure a continuing
source of maintenance service for it.

The hardware components traditionally consist of a small set of central medium-
sized computers and a large set of display terminals and printers distributed
throughout the hospital.  All of these elements are interconnected by means of
a standard high speed communication network.  The computers execute the
software and include large disk subsystems containing the permanent and common
clinical and financial records of the hospital.
<PAGE>  4
Hardware technology evolves rapidly, and the current trend is to replace the
display terminals with desktop computers, thereby forming a client server
network.  In this mode of operation, the central computers become the file
servers while software is executed locally on the client computer which makes
common file requests to the servers.

LICENSED SOFTWARE

MEDITECH requires a customer to sign a standard software license agreement
prior to product delivery, implementation and subsequent service of the
software.  This agreement specifies a front end product fee and a front end
implementation fee both of which are payable over the implementation process,
and a monthly service fee after the site goes live.  In addition to precluding
ownership and restricting transfer, the license mandates the hospital hold
MEDITECH harmless from any liability arising from incorrect operation of the
software.

MEDITECH bases its product fee on the total number of hospital beds that a
customer operates at all of its sites, and sets its implementation fee on the
total number of sites.  Large hospitals pay more than small hospitals, but
incremental fees continue to diminish.  The monthly service fees are always 1%
of the product fees.  A typical 250 bed acute care hospital might incur a
$500,000 product fee, $100,000 implementation fee and a $5,000 monthly service
fee.  An order is booked and goes into the backlog when a signed software
license and 10% of both front end fees are received.

STAFF ORGANIZATION

MEDITECH is organized into functional units grouped around product development,
sales and marketing, implementation, customer service, accounting and facility
operations.  All MEDITECH staff work in company owned buildings located in the
greater Boston area.

From its inception, MEDITECH utilized communication technology which allowed
much of its business activities to be performed by remote access.  MEDITECH
staff sitting at their desks may access client hospitals, both personnel and
computers.  The need for remote offices is thereby negated.  Although most
customer contact is through the phone, certain of the sales and implementation
staff travel to customer sites.

PRODUCT DEVELOPMENT

Most of the product development staff is working on the incremental evolution
of the current product line, as well as creating a few more new products each
year.  The rest of the staff is developing a set of replacement products
utilizing a new technology.  Approximately every seven years, the company
introduces the next generation of products based on the new technology and
gradually updates existing customers.
<PAGE>  5
SALES AND MARKETING

Most of the direct sales staff, organized into regions, concentrate on new
prospects.  In addition, some of the sales staff monitor existing customers to
expose them to the Company's entire product line.  Marketing activities and
promotion are low key because hospitals are easily identified, finite in number
and generally send an RFP to vendors when they are contemplating the purchase
of a hospital information system.

During the sales process, prospects generally visit MEDITECH to talk to product
specialists and to view product demonstrations.  Thereafter they are encouraged
to visit various MEDITECH customer sites to observe first hand the software in
actual operation and to discuss issues of concern with hospital personnel.

IMPLEMENTATION PROCESS

To ensure a successful implementation, the staff must properly train a core
group of hospital personnel.  To preclude interruptions from normal hospital
activities, MEDITECH mandates that the hospital personnel come to Boston for
intensive training sessions.

As training proceeds, the implementation staff will customize certain
dictionaries to fit the specific need of the hospital's environment, provide
interfaces to non-MEDITECH systems and to assist the hospital in converting
data from legacy systems.  In addition, the licensed software will be
delivered, installed and tested on the customer's hardware.  MEDITECH will
utilize remote access communication technology to minimize or eliminate the
need to travel.

CUSTOMER SERVICE

Once a hospital goes live, the responsibility of maintaining the customer is
transferred to the service staff.  MEDITECH provides 24 hour a day service
coverage to these customers in order to respond to problem calls.  In addition,
the staff updates customers with new releases of the software products as they
become available.  To ensure the continuing education of the hospital staff,
MEDITECH runs seminars on the use of its products.

COLUMBIA HEALTH CARE

Columbia/HCA owns and operates over 350 hospitals in the U.S., Canada, and the
U.K. and is MEDITECH's largest customer.  By the end of 1997 MEDITECH had
implemented approximately 300 of their hospitals.  They represented about 21%
of revenue in 1996 and 1997.  In the 3rd quarter of 1997 Columbia/HCA underwent
a major change in leadership and since then they have made public statements to
the effect that they are undergoing a transition in business strategy and will
be downsizing.  While it is difficult to predict how this will effect MEDITECH,
it may result in a decline in the revenue generated from them.

    ITEM 2 - Properties

As of December 31, 1997 the Company owned five facilities containing about
1.1 million square feet of space, all being well maintained Class A properties
in the greater Boston area.  The Company occupies 60% of the space and the
remaining 40% is leased to various tenants.  The Company has adequate space
for its reasonable needs over the next few years.

<PAGE>  6
    ITEM 3 - Legal Proceedings

There are no material pending legal proceedings against the Company, nor were
any initiated during the year 1997.

    ITEM 4 - Submission of Matters to a Vote of Security Holders

None.

PART II

    ITEM 5 - Market for Registrant's Common Equity and Related
             Stockholder Matters

No trading market exists for the Company's Common Stock, and accordingly no
high and low bid information or quotations are available with respect to the
Company's Common Stock.

The Company's Common Stock is subject to right of first refusal restrictions
upon sale, assignment, transfer, pledge or other disposition of any of its
shares.

At December 31, 1997 there were 747 holders of record of its Common Stock and
16,087,212 shares outstanding.

The Company paid quarterly cash dividends totaling the following amounts in the
most recent three fiscal years:

                       1995    1996    1997
    Per Share         $1.24   $1.40   $1.68

    ITEM 6 - Selected Financial Data
<TABLE>
For the Five Years Ended December 31, 1997 (in thousands where applicable):
<CAPTION>
                                   1993      1994      1995      1996      1997
<S>                            <C>       <C>       <C>       <C>       <C>
Operations:
    Revenue                    $105,325  $124,223  $143,721  $167,884  $193,805
    Operating Income             41,285    51,255    58,513    69,550    78,286
    Net Income                   29,625    32,190    37,085    44,350    50,284
    Average shares               15,523    15,641    15,782    15,863    16,029
    Earnings per share             1.91      2.06      2.35      2.80      3.14

Financial Position:
   Cash and cash equivalents     $6,191   $12,907    $6,512   $18,063    $8,379
   Total assets                 118,923   137,755   197,998   218,339   263,108
   Total liabilities             18,870    20,006    60,170    55,871    73,577
   Shareholders' equity         100,053   117,749   137,828   162,468   189,531
   Book Value per share            6.43      7.51      8.71     10.19     11.78
   Shares outstanding            15,567    15,686    15,831    15,938    16,087

Other Data:
   Working Capital              $43,027   $60,711   $47,573   $60,373   $44,911
   Cash flows from operations    26,615    35,218    41,443    56,413    62,195
   Depreciation                   3,459     3,294     4,809     6,155     9,084
   Cash dividends per share       $0.87     $1.04     $1.24     $1.40     $1.68
</TABLE>
<PAGE>  7
    ITEM 7 - Management's Discussion and Analysis of Financial
             Condition and Results of Operations

Comparison of Fiscal Years Ended December 31, 1996 and 1997:

1997 Revenue increased 15% to $193.8 million, while 1997 Operating Income
increased only 13% to $78.3 million.  During the 4th quarter the Company
experienced a decrease in the product revenue attributable to a slowdown in
implementations for Columbia/HCA.  During the quarter staff size was not
reduced in response.  The result of this caused growth in Operating Expenses
to exceed growth in Revenue.  1997 Operating Expenses increased 17% to
$115.5 million due to a 12% increase in staff size, a moderate increase in
employee salary and a significant increase in depreciation.

1997 Other Income, net of Other Expense, increased from $4.4 million to $6.4
million due to an increase of $3.3 million in rental income offset by a
one-time gain of $1.4 million on the 1996 sale of our Cambridge facility.

The Company's effective tax rate increased from 40% to 41% in 1997.

Comparison of Fiscal Years ended December 31, 1995 and 1996:

Revenue increased 17% from $143.7 million in 1995 to $167.9 million in 1996.
This increase is a result of increased orders from both existing and new
customers, with 28% of the increase attributable to Columbia/HCA, the Company's
largest customer.

Operating Expenses increased 15% from $85.2 million in 1995 to $98.3 million in
1996.  The primary reason for this increase is the costs associated with a 14%
increase in staff size from 1995 to 1996.

Other Income, net of Other Expense, increased from $1.2 million in 1995 to $4.4
million in 1996 due primarily to: a decrease in interest expense on bank note
($1.2 million); an increase in rental income ($0.9 million) and a gain on the
sale of our Cambridge facility ($1.4 million).

Income Tax Expense increased from $22.6 million in 1995 to $29.6 million in
1996.  1995's effective tax rate of 38% was a result of an investment tax
credit earned in 1995 on property purchased.  1996's effective tax rate was
40%.
<PAGE>  8
    ITEM 8 - Financial Statements and Supplementary Data

The Financial Statements are included as part of Exhibit 13 (Annual Report to
Shareholders)
<TABLE>
OPERATING RESULTS BY QUARTER:

For the Two Years Ended December 31, 1997 (in thousands where applicable):
<CAPTION>
                                Mar 31    Jun 30    Sep 30    Dec 31
<S>                            <C>       <C>       <C>       <C>
1996
   Revenue                     $38,843   $40,309   $41,856   $46,876
   Operating Income             15,575    16,163    17,278    20,534
   Net Income                    9,745    10,232    11,126    13,247
   Earnings per share              .61       .65       .70       .84
1997
   Revenue                     $46,705   $49,462   $51,184   $46,454
   Operating Income             19,310    20,448    20,998    17,530
   Net income                   12,201    12,838    13,507    11,738
   Earnings per share              .76       .80       .84       .73
</TABLE>
    ITEM 9 - Changes in and Disagreements with Accountants on
             Accounting and Financial Disclosure

None.

PART III

    ITEM 10 - Directors and Executive Officers of the Registrant

The positions held by each Director and Officer of the Company are shown below.
There are no family relationships among the following persons.

Name of Director or Executive  Age    Position with the Company
Officer

A. Neil Pappalardo              55    Chief Executive Officer, Chairman of
                                      the Board and Director
Lawrence A. Polimeno            56    Chief Operating Officer, President and
                                      Director
Morton E. Ruderman              61    Director
Jerome H. Grossman              58    Director
Edward B. Roberts               62    Director
Roland L. Driscoll              67    Director
L.P. Dan Valente                67    Director
Howard Messing                  45    Executive Vice President
Barbara A. Manzolillo           45    Chief Financial Officer, Treasurer and
                                      Assistant Clerk
Edward G. Pisinski              54    Senior Vice President
Roberta E. Grigg                54    Senior Vice President
Christopher J. Anschuetz        45    Vice President
Robert S. Gale                  51    Vice President
Steven B. Koretz                45    Vice President
Stuart N. Lefthes               44    Vice President
Joanne Wood                     44    Vice President
Jane E. Currier                 45    Chief Corporate Counsel and Clerk
<PAGE>  9
All Directors are elected each year at the annual meeting of shareholders.  All
executive officers are elected at the first meeting of the Board following the
annual meeting of shareholders and hold office for one year.  The Board of
Directors has an Audit Committee, an Executive Compensation Committee, and a
Charitable Contribution Committee.

The following is a description of the business experience during the past five
years of each Director and Officer.

A. Neil Pappalardo, founder of the Company, is the Chief Executive Officer and
Chairman of the Board, and has been a Director since 1969.

Lawrence A. Polimeno is the President and Chief Operating Officer, has been a
Director since 1985, and has been with the Company since 1969.

Morton E. Ruderman, Chief Executive Officer of CRES Development, has been a
Director since 1969.

Jerome H. Grossman, Chief Executive Officer of Health Quality, Inc., has been
a Director since 1970.

Edward B. Roberts, Professor at Sloan School, Massachusetts Institute of
Technology, has been a Director since 1969.

Roland L. Driscoll, retired Chief Financial Officer of the Company, has been
a Director since 1985.

L.P. Dan Valente, Chief Executive Officer of Palomar Medical Technologies,
Inc., has been a Director since 1972.

Howard Messing has been the Executive Vice President since 1995, was a Vice
President prior to that, and has been with the Company since 1974.

Barbara A. Manzolillo has been the Chief Financial Officer since 1996, was
the Treasurer prior to that, and has been with the Company since 1975.

Edward G. Pisinski has been a Senior Vice President since 1997, was a Vice
President prior to that, and has been with the Company since 1973.

Roberta E. Grigg has been a Senior Vice President since 1997, was a Vice
President prior to that, and has been with the Company since 1975.

Christopher J. Anschuetz has been a Vice President since 1995, was a Senior
Manager prior to that, and has been with the Company since 1975.

Robert S. Gale has been a Vice President since 1995, was a Senior Manager
prior to that, and has been with the Company since 1976.

Steven B. Koretz has been a Vice President since 1997, was a Senior Manager
prior to that, and has been with the company since 1982.

Stuart N. Lefthes has been a Vice President since 1997, was a Senior Manager
prior to that, and has been with the company since 1983.

Joanne Wood has been a Vice President since 1995, was a Senior Manager prior
to that, and has been with the Company since 1983.
<PAGE> 10
Jane E. Currier has been the Chief Corporate Counsel and the Clerk since
1986, and has been with the Company since 1983.

There were no failures to file or late filings under Section 16(a)

   ITEM 11 - Executive Compensation

The following table sets forth the compensation received by the Company's Chief
Executive Officer and the four most highly compensated other Officers for the
three fiscal years ended December 31, 1995, 1996 and 1997.

SUMMARY COMPENSATION TABLE

Name and Principal Position Year    Salary ($)  Bonus ($)   Other ($)

A. Neil Pappalardo          1997       360,000    727,676           0
 Chairman and Chief         1996       360,000    725,000           0
 Executive Officer          1995       360,000    725,000           0

Lawrence A. Polimeno        1997       240,000    627,676       6,042
 President and Chief        1996       240,000    625,000       5,962
 Operating Officer          1995       240,000    575,000       6,130

Howard Messing              1997       180,000    377,676       6,042
 Executive Vice President   1996       156,000    375,000       5,962
                            1995       156,000    275,000       6,130

Edward G. Pisinski          1997       156,000    302,676       6,042
 Vice President - Marketing 1996       156,000    300,000       5,962
                            1995       156,000    225,000       6,130

Barbara A. Manzolillo       1997       144,000    227,676       6,042
   Chief Financial Officer  1996       132,000    225,000       5,962
   and Treasurer            1995       132,000    175,000       6,130

Compensation of Executive Officers:  There are no employment contracts or
agreements in effect for any Officer of the Company.  The Board of Directors
authorizes and directs the bonus program instituted for the recognition of
services rendered by employees.  The total amount of the bonus pool is based on
a fixed percentage of operating income as set by the Board of Directors.  This
philosophy aligns the interest of all with the interests of the Company's
shareholders.

The Board of Director's Executive Compensation Committee (composed of Mr.
Roberts and Mr. Ruderman) sets Mr. Pappalardo's bonus compensation based upon
the same criteria for awarding bonuses to all officers and employees.

Pension Plan:  The Company maintains a qualified defined contribution plan for
all employees known as the Medical Information Technology, Inc. Profit Sharing
Plan.  All employees of the Company who have completed one year of service
participate in the plan.  The Company's annual contribution is allocated in
proportion to total compensation (capped at $100,000) of all eligible members
for the plan year.  No allocation is allowable under this plan to owners of 10%
or more of the Company's common stock.  Contributions by members are not
permitted.  Benefits under the plan become fully vested after five years of
continuous service with the Company.  Lump sum cash payment is made upon
retirement, death, disability, or termination of employment.
<PAGE> 11
Compensation of Directors:  The members of the Board of Directors who are not
Officers of the Company currently receive a fee of $7,000 for each fully
attended quarterly meeting, with such fee being deemed to also cover any
incidental expenses or directorial conference or committee time expended by
such directors in behalf of the Company during the year.

    ITEM 12 - Security Ownership of Certain Beneficial Owners
              and Management

The following table provides information as of December 31, 1997 with respect
to the shares of Common Stock beneficially owned by each person known by the
Company to own more than 5% of the Company's outstanding Common Stock, each
Director of the Company, each Executive Officer named in the Summary
Compensation Table and by all Directors and Executive Officers of the Company
as a group.  The number of shares beneficially owned is determined according to
rules of the Securities and Exchange Commission.  Under such rules, a person's
beneficial ownership includes any shares as to which such person has sole or
shared voting power or investment power.

                                  Number of Shares
                                   of Common Stock    % of Shares of
Name                            Beneficially Owned    Common Stock

A. Neil Pappalardo                       4,271,406        26.55%
Morton E. Ruderman                       2,357,919        14.66%
Jerome Grossman                            600,675         3.73%
Lawrence A. Polimeno                       572,850         3.56%
Edward B. Roberts                          374,113         2.33%
Roland L. Driscoll                         264,000         1.64%
Edward G. Pisinski                         147,500           <1%
Howard Messing                             125,000           <1%
Barbara A. Manzolillo                       80,000           <1%
L. P. Dan Valente                           42,500           <1%
Directors and Executive Officers
   as a Group (17 persons)               9,040,113        56.19%
Curtis W. Marble                         1,865,052        11.59%
Medical Information Technology Inc.
   Profit Sharing Trust                  1,469,010         9.13%

The address of all Executive Officers and Directors is in care of the Company,
MEDITECH Circle, Westwood, MA 02090.

    ITEM 13 - Certain Relationships and Related Transactions

None.
<PAGE> 12
PART IV

    ITEM 14 - Exhibits, Financial Statement Schedules, and Reports
              on Form 8-K

Exhibit 3i (Articles of Incorporation) and Exhibit 3ii (By-Laws) are
incorporated by reference from the registration statement on Form 10 effective
April 27, 1996 and from exhibit under Item 6 on Form 10-Q for the quarter ended
June 10, 1997 (Amendment to By-Laws), File # 0-28092.

Exhibit 13 (Annual Report to Shareholders) and Exhibit 27 (Financial Data
Schedule) are appended to this document.

There were no reports filed on Form 8-K during the quarter ended December 31,
1997.

    Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Medical Information Technology, Inc.
(Registrant)

March 24, 1998
(Date)

Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)